Key Takeaways
- B. Riley reduced Oklo’s price target to $92 from $129 while maintaining its Buy recommendation
- Needham slashed its target from $135 down to $73 but retained a Buy rating, suggesting approximately 20% potential upside
- Craig-Hallum decreased its price target to $71 from $87, keeping a Hold rating due to escalating capital requirements
- CEO Jacob Dewitte and CFO Richard Bealmear each offloaded approximately 72,000 shares at $60 per share on March 13; total insider sales reached ~$170M over 90 days
- Meanwhile, Oklo’s Atomic Alchemy division secured a DOE Nuclear Safety Design Agreement and an NRC materials license
The past six months have been challenging for Oklo’s stock performance. Currently trading around $60.76, the nuclear energy firm has experienced a 42% decline during this period, sitting significantly below its 52-week peak of $193.84.
Multiple Wall Street firms adjusted their price targets downward this week after reviewing the company’s fourth quarter 2025 earnings results. While targets dropped considerably, most analysts remain cautiously optimistic — they’re simply resetting expectations.
B. Riley decreased its target to $92 from $129 while maintaining a Buy recommendation. The firm highlighted meaningful operational achievements: Department of Energy approvals for the Aurora facility at Idaho National Laboratory, a prepayment deal with Meta covering up to 1.2 gigawatts in Ohio, initial fuel facility development, and regulatory achievements for its Atomic Alchemy isotope division.
Needham similarly maintained its Buy rating despite dramatically reducing its target from $135 to $73. This revised target still suggests roughly 20% potential upside from present levels, while the Street’s consensus target hovers around $94.80 with a “Moderate Buy” rating overall.
Craig-Hallum adopted a more conservative stance. The firm maintained its Hold rating while trimming its target from $87 to $71. Analysts revised their models to reflect elevated operating expenses, higher capital expenditure requirements, and adjusted timing projections for future capital needs. The firm also excluded projected 2026 isotope revenue — anticipated to be under $5 million — from its forecasts until greater visibility emerges.
Growing Capital Requirements and Executive Share Sales Create Concerns
Oklo concluded Q4 2025 holding $1.4 billion in cash reserves. Following the quarter’s end, it secured another $1.2 billion in financing. For 2026, management projects operating cash consumption between $80 million and $100 million, alongside investing cash use ranging from $350 million to $450 million.
Despite this cash cushion, the company reported a trailing twelve-month EBITDA loss of $97 million and a full-year 2025 operating loss totaling $139.3 million. Wall Street analysts don’t anticipate profitability arriving this year.
Compounding investor anxiety, CEO Jacob Dewitte offloaded approximately 72,960 shares on March 13 at $60 per share, generating roughly $4.38 million. CFO Richard Bealmear sold 72,090 shares the same day at an identical price, netting approximately $4.33 million. During the past 90 days, company insiders have collectively sold about 2.07 million shares valued at approximately $170 million total. Insiders currently maintain an 18.9% ownership stake in the company.
Regulatory Achievements Provide Silver Lining
Not all developments point downward. Oklo’s Atomic Alchemy subsidiary obtained a DOE Nuclear Safety Design Agreement for its Groves isotopes test reactor. Additionally, it secured an NRC materials and isotope license — marking Oklo’s first NRC license obtained through an acquired subsidiary.
The company’s Aurora reactor earned its initial design approval from the Department of Energy, a critical milestone for advancing a 1.2-gigawatt power supply arrangement with Meta, with energy delivery scheduled by 2034.
William Blair confirmed an Outperform rating. Cantor Fitzgerald maintained an Overweight rating with a $122 price target. Barclays holds an Overweight rating with an $82 target. Bank of America maintains a Buy rating with a $127 target.
Oklo’s 50-day moving average currently sits at $75.08 while its 200-day moving average rests at $95.27. The company maintains a market capitalization of approximately $9.49 billion.
